BCG和IL－2膀胱灌注预防膀胱癌复发的疗效观察

为了解ＢＣＧ＋ＩＬ－２联合应用膀胱灌注预防膀胱癌术后复发的疗效，将６０例膀胱癌随机分为两组：一组用ＢＣＧ６０ｍｇ（常用量的１／２）＋ＩＬ－２１００００Ｕ，一组用丝裂霉素Ｃ２０ｍｇ行膀胱内灌注。随访１０～４８个月，平均３３个月，无肿瘤复发者ＢＣＧ＋ＩＬ－２组２６例（８６．７％），丝裂霉素Ｃ组２３例（７６．７％），两组比较有显著性差异。ＢＣＧ＋ＩＬ－２组除有２４小时后自限性的轻微膀胱刺激症状外，无骨髓抑制等全身毒副反应。结果表明，ＢＣＧ＋ＩＬ－２较丝裂霉素Ｃ能更有效地防止膀胱癌术后复发，且可减少ＢＣＧ剂量。

BCG and IL-2 intravesical instillation in the prevention of postoperative recurrence of bladder tumor

For the prevention of tumor recurrence,intravesical instillation of a combination of 10 000 units of IL-2 and 60mg of BCG(half the conventional dose)was instituted postoperatively in 30 cases of bladder cancer and intravesical instillation of 20mg MMC in another 30.In the former group, 86.7%(27/30) have been free of tumor for a mean time of 33 months(ranging from 10 to 48 months)and in the latter group,76.7 %(23/30)have been free of tumor for the same period. Side effects after IL-2 and BCG instillation have been minor.Decreased dose of BCG with the additional use of IL-2 is recommended for intravesical instillation so as to reduce the postoperative recurrence rate of bladder cancer.